Compare ADMA Biologics Inc (ADMA) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Health Care Select Sector SPDR Fund — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while Health Care Select Sector SPDR Fund trades at $163.15. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | XLV | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $164.48 |
52-Week Low | $7.60 | $129.01 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
XLV trades at $162.06, down 1.03% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The healthcare ETF benefits from defensive sector positioning amid market volatility, with recent news highlighting healthcare as a safe haven during choppy markets. A dividend of $0.66 is scheduled for June 2026, providing income appeal.
Outlook remains positive given healthcare's defensive characteristics and innovation momentum in biotech and pharmaceuticals. Key risks include sector-specific regulatory pressures and patent cliff concerns for major holdings. Analyst sentiment leans bullish with technical support at $160 and resistance at $164.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
